Results 231 to 240 of about 29,283 (270)
ctDNA as a cancer biomarker: A broad overview
Critical Reviews in Oncology/Hematology, 2020 Circulating tumor DNA (ctDNA) in fluids has gained attention because ctDNA seems to identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of treatment, and prognosis: the so-called liquid biopsy. Liquid biopsy is a minimally invasive approach and presents the sum of ctDNA from primary and secondary tumor sites. It has been
Valeria Pereira Ferrer
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Chasing ctDNA in Patients With Sarcoma
American Society of Clinical Oncology Educational Book, 2020Liquid biopsies are new technologies that allow cancer profiling of tumor fragments found in body fluids, such as peripheral blood, collected noninvasively from patients with malignancies. These assays are increasingly valuable in clinical oncology practice as prognostic biomarkers, as guides for therapy selection, for treatment monitoring, and for ...
Catherine C, Coombs +2 more
openaire +2 more sources
Methods for Measuring ctDNA in Lymphomas
2018Plasma cell-free DNA (cfDNA) is an easily accessible source of tumor DNA that allows accurate profiling of lymphoma patients, representing a complementary source of tumor DNA to tissue biopsy for genotyping. Applications of cfDNA analysis in lymphomas include: (1) identification of tumor mutations in a biopsy-free manner; (2) tracking tumor clonal ...
Rossi, Davide +3 more
openaire +5 more sources
ctDNA: Moving toward Clinical Utility
Cancer Discovery, 2022Abstract Findings from the phase II DYNAMIC study suggest that circulating tumor DNA analyses could help clinicians decide whether patients with stage II colon cancer require chemotherapy after standard surgery. Liquid biopsies could also shed light on the development of resistance to KRASG12C inhibition, paving the way for better ...
openaire +2 more sources
Enrichment and Analysis of ctDNA
2019ctDNA provided by liquid biopsy offers a promising alternative to tumor biopsy as it gives a non-invasive and «real-time» access to the cancer genome and reflects tumor intra and extra heterogeneity. ctDNA has shown growing clinical interest for cancer diagnosis, prognosis, theragnostics, therapeutic monitoring, and clonal evolution tracking.
openaire +3 more sources
Review ctDNA and Breast Cancer
2019In only few years, circulating tumor DNA (ctDNA) in breast cancer has moved from purely fundamental research to nearby daily use for treatment selection and drug-resistance assessment. Indeed, technical advances and widespread use of next-generation sequencing or digital PCR allowed for detection of very low amount of tumor DNA in bloodstream.
openaire +3 more sources
Dynamic Treatment Stratification Using ctDNA
2019An accurate profiling of the genomic landscape is mandatory to establish the best clinical and therapeutic approach for patients with solid malignancies. Moreover, tumor cells constantly adapt to external pressures-i.e., systemic treatment-with the selection and expansion of resistant subclones and the emergence of heterogeneous overlapping genomic ...
Joana, Vidal +2 more
openaire +2 more sources
Abstract LB106: Ultra-short ctDNA: A new paradigm for ctDNA liquid biopsy
Cancer ResearchAbstract Mononucleosomal ctDNA (mnctDNA, 157-bp, double-stranded) spearheads liquid biopsy (LB) for cancer detection, treatment and clinical care. The bottleneck of mnctDNA LB are low copy number of ctDNA and limit of detection of platform technologies.
Feng Li +8 more
openaire +1 more source
Adjuvant Immunotherapy Best for ctDNA+ Bladder Cancer
Cancer Discovery, 2021Abstract A liquid biopsy may help identify patients with operable urothelial cancer who stand to benefit from adjuvant immunotherapy. In the IMvigor010 study, patients who tested positive for circulating tumor DNA showed improvement in disease-free survival and overall survival if they received adjuvant atezolizumab instead of ...
openaire +2 more sources